Gastroenterologia Japonica

, Volume 16, Issue 6, pp 568–575 | Cite as

Follow-up study in chronic active hepatitis after therapies with immunosuppressive drugs and tiopronin

  • Takao Tsuji
  • Hideo Nagashima
Original Articles


Follow-up studies were conducted in the patients with chronic active hepatitis treated 10 years ago with tiopronin (TP) or corticosteroids (CS). HB surface antigen (HBsAg) was measured in previously collected paraffin embedded liver sections by enzyme-labelled antibody technique. Of 72 cases examined, 15 cases were treated with TP only (8 cases) and combination with CS (7 cases), 38 cases with CS and 19 cases not treated with TP or CS (control group). Two deaths occurred in TP group (each 1 case in the single and combination treatments) in the 9th year due to bleeding of oesophageal varices in a chronic aggressive hepatitis (2B type) with HBsAg diffusely distributed in liver tissue. Two deaths were found in CS group and 4 in the control group. No significant difference was noted in the rehabilitation rate in HBsAg negative cases of TP group and CS group versus the control group. In the positive cases, the rehabilitation rate was found to be 66.7% in the CS group compared with 0% in the non-CS group, and each 3 cases out of 5 rehabilitated by the single and combination treatments with TP respectively.

Key Words

chronic active hepatitis chronic hepatitis corticosteroid therapy SH-compound therapy HBs antigen viral hepatitis type B liver diseases 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1).
    Tsuji T, Tokuyama K, Naito K, Okazaki S, Shinohara T, Araki K, Okada T, Nozaki H, Nagashima H: A case report of primary hepatic carcinoma with prolonged HB virus infection and monoclonal gammopathy. Gastroenterol Jpn 12: 69–75, 1977.PubMedGoogle Scholar
  2. 2).
    Ohta Y, Tsuji T, Nozaki H: Corticosteroid therapy in chronic hepatitis. Its reevaluation. Clin Immunol 7: 1145–1155, 1975 (Jpn)Google Scholar
  3. 3).
    Ohta Y, Tsuji T, Yoshida T, Yamada G, Kosaka K: Depolymerization of immunoglobulin M by α-mercaptopropionylglycine (Thiola) and its relation to rheumatoid factor in chronic liver diseases. Proceedings of the International Symposium on Thiola, Nov 25–26, 1970, Tokyo; 132–140Google Scholar
  4. 4).
    Kosaka K, Ohta Y, Tsuji T: A therapeutic effect of 2-mercaptopropionylglycine (MPG) on Australia antigen positive hepatitis. Proceedings of the Second International Symposium on Thiola, Dec 29–30, 1972, Jamaica; 79–88Google Scholar
  5. 5).
    Tsuji T, Naito K, Tokuyama K, Okada T, Kosaka K: Detection of HBs antigen in routine paraffin embedded liver tissue by enzyme-labelled antibody technique. Acta Med Okayama 30: 69–73, 1976PubMedGoogle Scholar
  6. 6).
    De Groote J, Desmet VJ, Gedigk P, Korb G, Popper H, Poulsen H, Scheuer PJ, Schmid M, Thaler H, Uhlinger E, Wepler W: A classification of chronic hepatitis. Lancet 2: 626–628, 1968PubMedGoogle Scholar
  7. 7).
    Tsuji T, Naito K, Tokuyama K, Okada T, Takata S, Araki K, Shinohara T, Inoue J, Onoue K, Tsuchiya M, Nozaki H, Nagashima H, Hayama K: Follow-up ten years after corticosteroid therapy for chronic active hepatitis type B. Hepato-Gastroenterology 27: 85–90, 1980PubMedGoogle Scholar
  8. 8).
    Baggenstoss AH, Soloway RD, Summerskill WHJ, Elveback LR, Schoenfield LJ: Chronic active liver disease. The range of histologic lesions, their response to treatment, and evolution. Human Pathol 4: 183–198, 1972CrossRefGoogle Scholar
  9. 9).
    Murray-Lyon IM, Stern RB, Williams R: Controlled trial of prednisolone and azathioprine in active chronic hepatitis. Lancet 1: 735–737, 1973PubMedCrossRefGoogle Scholar
  10. 10).
    Soloway RD, Summerskill WHJ, Baggenstoss AH, Geall MG, Gitnick GL, Elveback LR, Schoenfield LJ: Clinical, biological, and histological remission of severe chronic active liver disease. A controlled study of treatments and early prognosis. Gastroenterology 63: 820–833, 1972PubMedGoogle Scholar
  11. 11).
    Whelan G, Sherlock S: Immunosuppressive activity in patients with active chronic hepatitis and primary biliary cirrhosis treated with azathioprine. Gut 13: 907–914, 1972PubMedCrossRefGoogle Scholar
  12. 12).
    Cook GC, Mulligan R, Sherlock S: Controlled prospective trial of corticosteroid therapy in active chronic hepatitis. Quart J Med 40: 159–185, 1971PubMedGoogle Scholar
  13. 13).
    Geal MG, Schoenfield LJ, Summerskill WHJ: Classification and treatment of chronic active liver disease. Gastroenterology 55: 724–729, 1968Google Scholar
  14. 14).
    Summerskill WHJ, Ammon HV, Baggenstoss AH: Treatment of chronic hepatitis, In: The Liver and Its Diseases: ed by T Schaffner, S Scherlock, CM Leevy, International Medical Book Corporation, New York, 216–226, 1973Google Scholar
  15. 15).
    Ohta Y, Tsuji T: Immunosuppressive therapy on chronic liver diseases. Autoimmune phenomena and effects of immunosuppressive drugs in progress of chronic hepatitis. Clin Immunol 2: 55–70, 1970 (Jpn)Google Scholar

Copyright information

© The Japanese Society of Gastroenterology 1981

Authors and Affiliations

  • Takao Tsuji
    • 1
  • Hideo Nagashima
    • 2
  1. 1.Health Research CenterOkayama UniversityOkayamaJapan
  2. 2.The First Department of Internal MedicineOkayama University Medical SchoolOkayamaJapan

Personalised recommendations